Multinationals Score Three Out Four New China Priority Reviews
Executive Summary
Eight drugs from foreign multinationals, including Amgen’s Rapatha, Takeda’s Takecab, Sanofi’s Aubagio and UCB’s Cimzia, are among 12 products awarded priority new drug approval reviews in China under a scheme to speed up approvals and patient access that is also benefiting some domestic players.
You may also be interested in...
China JV Exit To Give Takeda More Focus, Cash
Takeda is selling its majority share in China biopharma joint venture Techpool to focus on its key growth areas in this market and raise cash ahead of the Shire acquisition, in a move that will also boost its former partner’s presence in manufacturing and critical care.
Can Takeda Help Deliver Shire's China Rare Disease Dream?
Coming out of the local integration with Baxter's spin-off Baxalta in China, Shire may have to face more uncertainties in the country despite erstwhile acquirer Takeda having a much larger presence there, while competition is also brewing for the merged company from rare disease heavyweights such as Roche and Biogen.
Pfizer Divests Select China Prevenar 13 Rights, Staff As Domestic Firms Gain Traction
Following in the steps of Merck & Co. and GSK, Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in the country - but the US firm is going one step further.